San Diego – November 29, 2016 – Cooley advised Flexion on its $70.2 million shelf-takedown of 4,140,000 shares of common stock, which included the full exercise of the underwriters’ option to purchase additional shares.
Flexion, which trades on The NASDAQ Global Market under the symbol “FLXN,” is a specialty pharmaceutical company focused on the development and commercialization of novel, local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis.
Cooley advised Flexion on its $75 million IPO in February 2014 and its subsequent follow-on offerings in December 2014 and June 2016.
About Cooley LLP
Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.
Cooley has 900 lawyers across 12 offices in the United States, China and Europe.